MEDTRONIC(R) SYNCHROMED(TM) PUMP & INFUSION SYSTEM
Medtronic, Inc. · Decision date Mar 14, 1988
What did the FDA approve?
FDA records P860004 as an original PMA application. The recorded decision is approval, dated Mar 14, 1988.
FDA approval order statement
Approval for the Medtronic SynchroMed Infusion System. This device is indicated for chronic intravascular infusion of floxuridine (FUDR) or doxorubicin hydrochloride (Adriamycin) and, when required bacteriostatic water, physiological saline and/or heparin.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General Hospital
- Decision date
- Mar 14, 1988
Regulatory record facts
- Identifier
- P860004
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic, Inc.
- Product code
- LKK
- Decision code
- APPR
- Decision date
- Mar 14, 1988
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pump, infusion, implanted, programmable.
- Applicant
- Medtronic, Inc.
- Product code
- LKK
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P860004 received
Application receipt date recorded by FDA.
P860004 · FDA decision
APPR
P860004/S462 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S458 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S464 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters TDD (Drug Delivery Infusion Pump 8667), TDD (Drug Delivery I
P860004/S465 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
Timeline entries are records held by MedtechLedger for P860004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P860004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 27, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 30, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P860004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records